Reducing the burden of orthodontic care for children with clefts: evaluating the effectiveness of pre-alveolar bone graft orthodontics in unilateral non-syndromic cleft patients (PABO study)— A study protocol for a multicentric randomised controlled trial

From Springer Nature via Jisc Publications RouterHistory: received 2021-05-12, registration 2021-08-02, accepted 2021-08-02, pub-electronic 2021-08-28, online 2021-08-28, collection 2021-12Publication status: PublishedFunder: Science and Engineering Board, Department of Science and Technology, Govt. of India; Grant(s): CRG/2019/005689Abstract: Background: An alveolar cleft commonly affects 75% of cleft lip and palate patients. While it is common practice to provide a course of orthodontic treatment before alveolar bone grafting, there are no previous high-quality studies reporting on the benefits of this type of treatment. Aim: The aim of the study is to evaluate the effectiveness of pre-alveolar bone graft orthodontics for unilateral non-syndromic cleft palate patients. Method: The PABO trial is a multicentric, parallel, two-arm, single-blinded randomised controlled trial. The inclusion criteria include unilateral cleft alveolus patients requiring bone graft and between the age group of 8 and 13 years with erupted upper central incisors. Participants will be recruited at three centres across India. Participants will be randomised to orthodontic treatment or no orthodontic treatment group. Both groups of participants will have alveolar bone graft surgery and will be followed up for 6 months after surgery. The primary outcome will be the success of the alveolar bone graft measured by anterior oblique radiograph and secondary outcomes include quality of life, cost analysis and quality of the dento-occlusal outcome. Data analysis will be carried out by an independent statistician at the end of the study. Discussion: This study is the first to evaluate the effect of orthodontics on alveolar bone graft success. The increased burden of care for these patients with multiple treatments required from multiple specialists from birth to adult life highlights the need for reducing unnecessary treatment provision. Trial Registration: Clinical Trials Registry – India, CTRI/2020/10/028756. Trial prospectively registered on 29 October 2020.

A multi-centric, single-blinded, randomized, parallel-group study to evaluate the effectiveness of nasoalveolar moulding treatment in non-syndromic patients with complete unilateral cleft lip, alveolus and palate (NAMUC study): a study protocol for a randomized controlled trial.

BACKGROUND Cleft lip and palate (CLP) are among the most common congenital anomaly that affects up to 33,000 newborns in India every year. Nasoalveolar moulding (NAM) is a non-surgical treatment performed between 0 and 6 months of age to reduce the cleft and improve nasal aesthetics prior to lip surgery. The NAM treatment has been a controversial treatment option with 51% of the cleft teams in Europe, 37% of teams in the USA and 25 of cleft teams in India adopting this methodology. This treatment adds to the already existing high burden of care for these patients. Furthermore, the supporting evidence for this technique is limited with no high-quality long-term clinical trials available on the effectiveness of this treatment. METHOD The NAMUC study is an investigator-initiated, multi-centre, single-blinded randomized controlled trial with a parallel group design. The study will compare the effectiveness of NAM treatment provided prior to lip surgery against the no-treatment control group in 274 patients with non-syndromic unilateral complete cleft lip and palate. The primary endpoint of the trial is the nasolabial aesthetics measured using the Asher McDade index at 5 years of age. The secondary outcomes include dentofacial development, speech, hearing, cost-effectiveness, quality of life, patient perception, feeding and intangible benefits. Randomization will be carried out via central online system and stratified based on cleft width, birth weight and clinical trial site. DISCUSSION We expect the results from this study on the effectiveness of treatment with NAM appliance in the long term along with the cost-effectiveness evaluation can eliminate the dilemma and differences in clinical care across the globe. TRIAL REGISTRATION ClinicalTrials.gov CTRI/2022/11/047426 (Clinical Trials Registry India). Registered on 18 November 2022. The first patient was recruited on 11 December 2022. CTR India does not pick up on Google search with just the trial number. The following steps have to be carried out to pick up. How to search: ( https://ctri.nic.in/Clinicaltrials/advsearch.php -use the search boxes by entering the following details: Interventional trial > November 2022 > NAMUC)

Facile stereoselective synthesis of the C12-C24 fragnent of macrolactin A

A simple and efficient stereoselective synthesis of the C12-C24 fragment of the natural product macrolactin-A was achieved from D-glucose as the starting material and with use of the Wittig and modified Julia olefination reactions as key steps

Facile addition of ketones to activated isoquinolines using N-methyl-2-pyrrolidinone

Ketones undergo a smooth addition to N-acylisoquinolinium ions in N-methyl-2-pyrrolidinone, under mild conditions, to produce 1-alkylated isoquinoline derivatives in excellent yields with high regioselectivity. The use of commercially available N-methyl-2-pyrrolidinone makes this process quite simple, more convenient and practical

Amberlyst A-21<SUP>®</SUP>: an efficient, cost-effective and recyclable catalyst for the synthesis of substituted 4H-chromenes

A variety of substituted 4H-chromene derivatives have been synthesized in good to excellent yields from o-hydroxybenzaldehydes and ethyl cyanoacetate or malononitrile in ethanol using inexpensive and reusable catalyst i.e., Amberlyst A-21® under mild reaction conditions. The recovered activated catalyst is recycled in five times subsequent runs with no decrease in activity. The use of reusable catalyst makes this procedure quite simple, more convenient, economically viable and environmentally friendly

Synthesis and cellular uptake of cell delivering 2,6-pyridinediylbisalkanamide submicron-sized sheets in HeLa cells

2,6-Pyridinediylbisalkanamides were synthesized, using diaminopyridine (DAP) as a linker and alkyl chains of varying lengths, that upon self-assembly form submicron-sized sheets and their uptake into the cytoplasm of HeLa cells was studied by confocal microscopy

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

IMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes